ArticleWorld journal of surgery2013
Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma.
Article in World journal of surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence.Langenbeck's archives of surgery · 2022Pooled it
- Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.Esophagus : official journal of the Japan Esophageal Society · 2019Guideline
- The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature.World journal of surgical oncology · 2018Pooled it
- Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.Journal of surgical oncology · 2018Trial
- Survival benefit of local treatment for oligo-recurrence after esophageal cancer surgery.World journal of surgical oncology · 2026Article
- Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases.World journal of gastrointestinal oncology · 2026Article
- Repeated lymph-node recurrences after radical endoscopic submucosal dissection in a patient of esophageal squamous cell carcinoma, judged as pT1a-LPM: a case report and literature review.Clinical journal of gastroenterology · 2025Review
- Development and validation of a prognostic prediction model for patients with lung metastasis of esophageal cancer.World journal of surgical oncology · 2025Article
- Multimodal therapy for oligometastases after curative esophagectomy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Oligometastatic disease - a renaissance for surgery?Innovative surgical sciences · 2025Review
- German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0.ESMO gastrointestinal oncology · 2025Review
- Impact of Lymphatic and Venous Invasion Patterns on Postoperative Prognosis and Distant Metastasis in Esophageal Squamous Cell Carcinoma After Preoperative Chemotherapy.Annals of surgical oncology · 2025Article
- Role of Proton Beam Therapy in Hepatic Oligometastasis: Review of Evidence.Acta medica Lituanic · 2025Article
- Development and validation of a prognostic model for patients with cT1-4N1-3M1 esophageal squamous cell carcinoma: based on the SEER database and the Chinese cohort study.Frontiers in oncology · 2025Article
- Use machine learning to predict pulmonary metastasis of esophageal cancer: a population-based study.Journal of cancer research and clinical oncology · 2024Article
- Surgical and multimodal treatment of metastatic oesophageal cancer: retrospective cohort study.BJS open · 2024Article
- Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer.Cureus · 2023Article
- The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients.Journal of radiation research · 2023Article
- The Prognostic Value of Oligo-Recurrence Following Esophagectomy for Esophageal Cancer.Journal of chest surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe assessed the benefit of hepatic and pulmonary resections in patients with liver and lung recurrences, respectively, after resection of esophageal carcinoma.
methodsThe study population consisted of 138 consecutive patients with recurrent esophageal carcinoma after esophagectomy conducted between 2003 and 2005. The pattern, timing of appearance, and the prognosis of these recurrences were investigated, paying particular attention to those undergoing hepatic and pulmonary resections.
resultsIn total, 55 and 92 patients developed locoregional and distant-organ metastases 13 and 6 months (median) after surgery, respectively, including 9 patients with both types of recurrence. The distant-organ metastases were found in the liver (n = 26), lung (n = 27), bone (n = 21), and other organs (n = 29). Patients with pulmonary recurrences had a better overall prognosis (median survival after recurrence detection 13 months) than those with hepatic metastases (5 months) or nonhepatic nonpulmonary metastases. (3 months) Hepatic and pulmonary resections were carried out in patients with oligonodular (n = ≤ 2) isolated liver and lung metastases (n = 5, respectively). Although the survivals of patients with lung metastases who were treated/not treated by pulmonary resection were different (median survival: 48 vs. 10 months, p < 0.01), the difference in the survivals between patients with hepatic metastases who were treated/not treated by hepatic resection reached only borderline statistical significance (13 vs. 5 months, p = 0.06).
conclusionsResection of pulmonary metastases yields a survival benefit in properly selected patients. The benefit of resection for hepatic metastases remains controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.